FDA
-
-
-
-
-
-
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
-
-
-
-
-
-
-
Cassava Sciences (SAVA) Reports FY23 Nets Loss of $97.2M, Provides Corporate Update
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Brooge, and Cassava and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
-
-
-
-
-
-
-
Cassava Sciences (SAVA) Announces New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
-
-
-
-
-
-
-
Cassava Sciences (SAVA) Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
-
-
-
-
-
-
-
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
-
251,413 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All